In a recent episode of the Denatured podcast, Jennifer C. Smith-Parker spoke with Erik Digman Wiklund, CEO of Circio, and Jacob Becraft, Co-founder and CEO of Strand Therapeutics, about the future direction of programmable RNA medicines.
The discussion centered on advancements in mRNA technology since its use in COVID-19 vaccines. While first-generation mRNA therapies have demonstrated the effectiveness of transient genetic instruction, challenges such as instability, immune reactivity, and short-lived expression have restricted their primary application to vaccines. New platforms like circular RNA and logic circuit RNA are now being explored to broaden therapeutic possibilities.
Jennifer Smith-Parker hosted the conversation as Director of Insights at BioSpace. The guests shared their perspectives on how these emerging technologies could impact medicine beyond current vaccine applications.
A disclaimer was included: "The views expressed in this discussion by guests are their own and do not represent those of their organizations."
